Small Pharma’s first phase clinical trials prove promising for DMT-assisted therapy
Our CMSO Carol Routledge spoke to Mental Health Today about Small Pharma and its history with psychedelic research, Phase I clinical trials and the research around a safe, well-tolerated DMT dose, as well as what’s on the horizon for Small Pharma and psychedelic-assisted therapy
On psychedelic-assisted therapy as a whole, Dr Routledge had lots to say including a discussion on the potential of psychedelic-assisted therapy to address the unmet mental health needs of millions of people.
I’ve worked in the pharmaceutical industry for a long time. I have worked on SSRIs in the past. I do think SSRIs are effective, but clearly in a very different way to psychedelic-assisted therapy. But they are not effective in all patients…And although effective, I don’t really think SSRIs get to the root cause. Whereas I do believe that psychedelic assisted therapy potentially could.”
READ THE FULL MENTAL HEALTH TODAY ARTICLE HERE